for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

IsoRay, Inc.

ISR.A

Latest Trade

0.38USD

Change

-0.02(-4.05%)

Volume

187,267

Today's Range

0.38

 - 

0.41

52 Week Range

0.29

 - 

1.06

As of on the NYSE MKT LLC ∙ Minimum 15 minute delay

Pricing

Previous Close
0.40
Open
0.40
Volume
187,267
3M AVG Volume
9.85
Today's High
0.41
Today's Low
0.38
52 Week High
1.06
52 Week Low
0.29
Shares Out (MIL)
68.90
Market Cap (MIL)
27.56
Forward P/E
--
Dividend (Yield %)
--

Latest Developments

More

Isoray Announces Fourth Quarter And Full-Year Fiscal Year End 2020 Financial Results

IsoRay Q3 Loss Per Share $0.01

Isoray Reports Q2 Loss Per Share $0.01

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About IsoRay, Inc.

IsoRay, Inc. is a medical technology company. The Company, through its subsidiary, IsoRay Medical, Inc., develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. The Company is engaged in the production and sales of Cesium-131 (Cs-131) brachytherapy seeds. Brachytherapy seeds are small devices containing a therapeutic dose of radiation used in an interstitial radiation procedure. The brachytherapy procedure places radioactive seeds as close as possible to (in or near) the cancerous tumor. The Cs-131 includes radioisotope in the treatment of all malignant tumors, such as prostate cancer, brain cancer, breast cancer, colorectal cancer, gynecological cancer, lung cancer, liver cancer, ocular melanoma and pancreatic cancer. The Company's Proxcelan Cesium-131 seed is classified as a Class II device.

Industry

Medical Equipment & Supplies

Contact Info

350 Hills St Ste 106

RICHLAND, WA

99354-5511

United States

+1.509.3751202

https://isoray.com/

Executive Leadership

Michael W. McCormick

Independent Chairman of the Board

Lori A. Woods

Chief Executive Officer, Director

Jonathan Robert Hunt

Chief Financial Officer, Co-Principal Financial Officer

Jennifer Streeter

Chief Operating Officer, Vice President of Human Resources

Michael Krachon

Executive Vice President of Sales and Marketing

Key Stats

2.00 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020

0.0K

2021(E)

0.0K
EPS (USD)

2018

-0.120

2019

-0.080

2020

-0.050

2021(E)

-0.055
Price To Earnings (TTM)
--
Price To Sales (TTM)
2.85
Price To Book (MRQ)
4.82
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-44.68
Return on Equity (TTM)
-38.03

Latest News

Latest News

BRIEF-Isoray's Cesium-131's Second Ten Year Data Report Demonstrates Efficacy

* SECOND TEN YEAR DATA REPORT DEMONSTRATES EFFICACY OF ISORAY’S CESIUM-131 INTERNAL RADIATION THERAPY IN THE TREATMENT OF PROSTATE CANCER

BRIEF-IsoRay Q3 Loss Per Share $0.01

* ISORAY ANNOUNCES RECORD THIRD QUARTER FISCAL 2020 FINANCIAL RESULTS

BRIEF-Isoray Entered Equity Distribution Agreement With Oppenheimer & Co

* ISORAY INC - ENTERED EQUITY DISTRIBUTION AGREEMENT WITH OPPENHEIMER & CO RELATING TO $15 MILLION SHARES Source text: https://bit.ly/3bymnpw Further company coverage:

BRIEF-Isoray Reports Q2 Loss Per Share $0.01

* ISORAY ANNOUNCES SECOND QUARTER FISCAL 2020 FINANCIAL RESULTS

BRIEF-Isoray Announces Disposable Delivery System For Custom Intra-Operative Strands For Prostate Cancer Treatment

* ISORAY ANNOUNCES THE FIRST DISPOSABLE DELIVERY SYSTEM FOR CUSTOM INTRA-OPERATIVE STRANDS FOR PROSTATE CANCER TREATMENT Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-IsoRay Inc Enters A Sales Agreement With H.C. Wainwright & Co

* ISORAY INC - ON MAY 8, 2018, CO ENTERED INTO A SALES AGREEMENT WITH H.C. WAINWRIGHT & CO., LLC - SEC FILING

BRIEF-Isoray Reports Q3 LOSS PER SHARE $0.02

* ISORAY ANNOUNCES THIRD QUARTER FISCAL 2018 REVENUE OF $1.57 MILLION, 23 PCT THIRD QUARTER-OVER-THIRD QUARTER INCREASE

BRIEF-Isoray Reports Q2 Loss Per Share Of $0.03

* ISORAY ANNOUNCES SECOND QUARTER FISCAL 2018 REVENUE OF $1.54 MILLION, 50 PCT SECOND QUARTER-OVER-SECOND QUARTER INCREASE

BRIEF-Isoray Inc Preliminary Q2 Revenue $1.54 Million

* ISORAY ANNOUNCES PRELIMINARY SECOND QUARTER F2018 REVENUE OF $1.54 MILLION, 50% YEAR-OVER-YEAR INCREASE

BRIEF-Isoray Says Notified Al & J Media Of Decision To Terminate Media Advertising Agreement Between Parties

* ISORAY SAYS ON DEC 29, 2017, CO NOTIFIED AL & J MEDIA INC OF ITS DECISION TO TERMINATE MEDIA ADVERTISING AGREEMENT BETWEEN PARTIES - SEC FILING Source text: (http://bit.ly/2CTpIiQ) Further company coverage:

BRIEF-IsoRay Q1 loss per share $0.03

* IsoRay announces first quarter fiscal 2018 financial results

BRIEF-IsoRay Inc announces the launch of a Phase II, multicenter clinical trial

* Announces the launch of a Phase II, multicenter clinical trial with Cesium-131 adjuvant radiation for Retroperitoneal Sarcoma Delivery System (Cards Trial) by University of Louisville, division of surgical oncology Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up